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BACKGROUND: Shared decision making improves val-
ue-concordant decision-making around prostate cancer
screening (PrCS). Yet, PrCS discussions remain com-
plex, challenging and often emotional for physicians
and average-risk men.
OBJECTIVE: In July 2011, the Centers for Disease
Control and Prevention convened a multidisciplinary
expert panel to identify priorities for funding agencies
and development groups to promote evidence-based,
value-concordant decisions between men at average
risk for prostate cancer and their physicians.
DESIGN: Two-day multidisciplinary expert panel in
Atlanta, Georgia, with structured discussions and
formal consensus processes.
PARTICIPANTS: Sixteen panelists represented diverse
specialties (primary care, medical oncology, urology),
disciplines (sociology, communication, medical educa-
tion, clinical epidemiology) and market sectors (patient
advocacy groups, Federal funding agencies, guideline-
development organizations).
MAIN MEASURES: Panelists used guiding interactional
and evaluation models to identify and rate strategies
that might improve PrCS discussions and decisions for
physicians, patients and health systems/society. Effi-
cacy was defined as the likelihood of each strategy to
impact outcomes. Effort was defined as the relative
amount of effort to develop, implement and sustain the
strategy. Each strategy was rated (1–7 scale; 7 =
maximum) using group process software (Think-
TankTM). For each group, intervention strategies were
grouped as financial/regulatory, educational, commu-
nication or attitudinal levers. For each strategy, barriers
were identified.
KEY RESULTS: Highly ranked strategies to improve
value-concordant shared decision-making (SDM) in-
cluded: changing outpatient clinic visit reimbursement
to reward SDM; development of evidence-based, tech-
nology-assisted, point-of-service tools for physicians
and patients; reframing confusing prostate cancer screen-
ing messages; providing pre-visit decision support inter-
ventions; utilizing electronic health records to promote
benchmarking/best practices; providing additional train-
ing for physicians around value-concordant decision-
making; and using re-accreditation to promote training.
CONCLUSIONS: Conference outcomes present an ex-
pert consensus of strategies likely to improve value-
concordant prostate cancer screening decisions. In
addition, the methodology used to obtain agreement
provides a model of successful collaboration around
this and future controversial cancer screening issues,
which may be of interest to funding agencies, educators
and policy makers.
KEY WORDS: prostate cancer screening; men’s health; shared decision-
making; communication; funding priorities; risk.
J Gen Intern Med 28(11):1410–9
DOI: 10.1007/s11606-013-2419-z
© The Author(s) 2013. This article is published with open access at
Springerlink.com
BACKGROUND
How can screening for life-threatening diseases be harmful?
While many screening tests have improved the quantity
and quality of a person’s life through early detection of life-
threatening or life-altering diseases, other tests have failed
to deliver. These tests may fail to deliver because they are
inaccurate, poorly performing, have unavailable treatments,
high costs, treatment complications or health providers who
are unaware of the screening controversies. Prostate cancer
screening with the prostate-specific antigen (PSA) blood
test epitomizes this controversy. Prostate cancer accounts
for about 29,000 cancer deaths annually in the US, yet
millions of men may have undetected prostate cancer—the
vast majority of whom will remain asymptomatic through-
out their life.1–4 At the population level, prostate cancer
treatment has only a marginal mortality benefit. PSA as a
screening test has reasonable sensitivity to detect aggressive
prostate cancers (91%), but cannot distinguish between low-
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and high-risk prostate cancers. This results in substantial
overdiagnosis (with attendant treatment complications of impo-
tence, incontinence and surgical mortality) of men who would
have remained asymptomatic.1–4
For controversial conditions such as prostate cancer
screening (PrCS), the medical encounter needs to focus on
discussion and education to help patients reach value-
concordant decisions.5–11 Value-concordant decision-making
can be enhanced using shared decision-making8 techniques to
clarify issues. In SDM, medical knowledge (risks, harms and
benefits of diagnosis and treatment) is cogently and clearly
contextualized through the lens of patient’s values and
preferences to elicit a preferred clinical pathway.
Most major professional societies have endorsed SDM for
decisions around prostate cancer screening for average-risk
men aged 55–75 years old.2,3,12–15 In 2010, the American
Cancer Society updated its PrCS recommendations to include
an informed decision-making/SDM discussion about screen-
ing with the PSA test for all men who had a longer than 10-
year life expectancy.15 Until recently, the US Preventive
Services Task Force (USPSTF) considered the evidence
insufficient to recommend for or against prostate cancer
screening in this age range, but they encouraged shared
decision-making.3 In 2011, the USPSTF recommended
against routine PrCS for average-risk men of all ages.3,16
Yet, balanced discussions between clinicians and patients
about disease screening remain problematic.17 Objective
disease screening discussions are colored by over 50 years
of public health efforts that convey “do not delay” messages
for cancer screening.18 Overall, the public has an enthusi-
asm for health screening. This enthusiasm for cancer
screening persists even when they understand the risks of
false-positive results-identifying “abnormalities” that have a
dubious impact on health but may result in a cascade of
costly and often aggressive medical interventions.19 At the
same time, physicians often worry about liability issues that
might arise from missed diagnosis resulting from a decision
not to screen.20,21 Primary care physicians have limited time
for complex medical discussions, have limited training in
effective SDM techniques6,8,22 and are often not up to date
on the latest evidence. Additionally, tension exists between
specialists who see patients with advanced disease (and
therefore push for aggressive screening) and primary care/
population health groups who see the myriad of complica-
tions from over-diagnosis.
As such, public and private agencies are seeking methods
to help patients make complex medical decisions that go
beyond providing written material or engaging in brief
discussions. Typically, health messages fail for a variety of
reasons: the type of message delivered5,23–26; method of
delivery; lack of message reinforcement; lack of access to
recommended care; non-acceptance on the part of the
individual; and inappropriate education level. Similarly,
expert consensus groups have identified strategies (Fig. 1)
to effectively empower patients facing value-sensitive
decisions—utilizing SDM, tailoring messages to match
cultural background, connecting messages to patient values,
assessing readiness to change, targeting messaging to
individuals or entities that influence decision-making by
the patient (e.g., spouse), utilizing direct patient stories and
using decision support interventions.23–27 New methods are
intended to engage, challenge and motivate patients to make
value-concordant health choices, but are not commonly
used in clinical practice.10,22,28–32
These uncertainties prompted the Centers for Disease
Control and Prevention (CDC) to convene a consensus
panel to help prioritize communication strategies—to assist
patients and physicians in communicating more effectively
around prostate cancer screening (PrCS), including PrCS
risks, benefits and value preferences. Panel recommenda-
tions were intended to help the CDC, public health
community and medical communities set priorities for
prostate cancer communication methods and in other areas.
Here, we describe the process for the panel, main results,
implications for PrCS and other health communication.
METHODS
The Multidisciplinary Expert Panel
The CDC convened an expert panel around PrCS commu-
nication on June 13–14, 2011, in Atlanta, Georgia. The
diverse panel was assembled with experts from across the
health care spectrum relevant to PrCS, including individuals
with expertise in primary care, oncology, urology, epidemi-
ology, medical education, journalism, health communica-
tion and patient advocacy. Participants also included authors
of the USPSTF prostate cancer screening evidence report/
guidelines and experts from the CDC’s Division of Cancer
Prevention and Control (invited panelists listed in Acknowl-
edgements).
Methods
Prior to the in-person meeting, panelists were assigned to
one of three groups (health care provider, patient, health
system) based on their background. Groups met by
conference call 1–2 times prior to the in-person meeting to
share their prostate cancer screening research and experi-
ences and to discuss the literature in their assigned area.
Panelists were asked to accept the PrCS recommenda-
tions by the USPSTF 2008 rather than engage in debate
around the value of population-based PrCS. Specifically, at
the time of the panel, USPSTF 2008 guidelines concluded
the evidence was insufficient to assess the balance and
harms of PrCS in men younger than 75 years old, with a
recommendation for SDM to determine individualized
screening decisions.2
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Early in the meeting, three didactic sessions of
60 min each reviewed the state of the science around
prostate cancer screening communication. The first
focused on clinician-patient communication, the second
focused on patient-directed communication (helping
patients make more informed and value-concordant
screening decisions) and the third focused on health
systems (e.g., system change, electronic health records,
reminder systems and social networking). Following
each session, panelists discussed methods to improve
communication around PrCS focused on the target
groups (providers, patients and health systems) with
attention to target audiences, specific messaging, health
literacy, media and communication channels and pro-
gram evaluation.
To promote maximum participation and prioritization of
ideas by all panelists, we provided each panelist with a
laptop computer loaded with “ThinkTank” (GroupSystems,
2011) software. The software allows continuous input of
anonymous comments during ongoing discussions and
allows all panelists an equal opportunity to express their
opinions, preventing individuals from dominating the
conversation.
After each session, panelists identified the greatest
opportunities to improve decision-making around pros-
tate cancer screening communication. Individuals entered
their ideas into ThinkTankTM, and ideas were anony-
mously projected on a screen for group discussion.
Responses were edited and condensed by the facilitator
and group, after which each panelist anonymously rated
each response on a 7 point scale (1–7, 1 = minimum,
7 = maximum) for on two domains: (1) effectiveness:
likelihood that appropriate implementation of the communi-
cation strategy would lead to meaningful improvement in
PrCS decision-making and (2) feasibility/effort: the effort
required to successfully implement each strategy.
Responses and ratings were displayed for group dis-
cussion, and agreement was achieved for major strategies.
Panelists listed barriers to each strategy and methods
needed to overcome them. We reviewed models of cancer
communication,33 and based on participant discussion,
utilized that discussion to develop an interactional model
of elements that might influence patient–physician decision-
making around PrCS.
Using ThinkTank software, we grouped PrCS strate-
gies into three areas: those intended for providers,
patients and health care systems/public health. We then
divided the strategies into five content areas: (1)
education/knowledge, (2) financial/regulatory, (3)
beliefs/attitudes, (4) messaging and (5) communication/
decision-making. For each action, the group discussed
benefits and barriers.
RESULTS
Model Development
Based on panelist discussion, we developed a model of
elements that influenced patient and physician deci-
sion-making. The model suggests that patient decisions
occur after they have been informed (via physician,
health system, decision support interventions, etc.) and
have clarified their preferences, values and risk
tolerance.
In the model, we only considered influences on the
patient–physician interaction, including the knowledge,
experience, biases and health literacy of the patient and
the physician. Patient decisions were felt to be influ-
enced by their willingness to participate in decision-
making, trust of the clinician and the source of
information, the value they placed on health, the opinion
and experiences of family/friends, time and access
issues, and competing interests (e.g., financial). Physi-
cian advice and decision-making might also be influ-
enced by extreme exemplar cases, limited time to
engage in discussions, exposure to opinion leaders/
CME and institutional policies including quality assur-
ance metrics and competing interests (e.g., patient co-
morbidities, professional duties). During physician and
patient interaction, we assumed that decision-making
would involve explanation of content, contextualization
of risk-reward, elicitation of values and screening
recommendations.
As we further developed the model, we considered
contextual elements that influenced the patient-physi-
cian interaction, nested in a larger societal and health
system context (Fig. 1; expanded Appendix 1). In this
model, some patient and physician elements are
influenced by context, while others are intrinsic to
the individual. Patients interact directly with and are
partially influenced by their society and health system.
Physicians interacted with and were partially influ-
enced by their health system(s) and societal factors.
Finally, society and the health system interact to set
the tone, funding and expectations for improved care.
The intersection of all of these forces is the point of
decision-making.
Participants acknowledged the complexities in making
sound, personalized health care decisions around cancer
screening—especially prostate cancer. Participants also
identified a large number of activities that could improve
communication and decision-making.
Physicians. The group identified many barriers to
optimal shared decision-making (SDM), but the two
judged most important were (1) a shortage of physician
time and (2) physician skill at engaging in such
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discussions. The group identified several communication
interventions that might improve these shortcomings.
Traditional attempts to provide patients with information
or empowerment tools utilized brochures and printed
messages. Technology-assisted learning now opens
opportunities to tailor messages to individual patients,
allows interactions between groups of people and
collects information from patients that can better
inform the health care team.
Based on group ranking regarding strategies to
address physician communication issues (Table 1), inter-
ventions felt most likely to be effective were (1)
changing reimbursement for physicians to promote them
spending more time in doctor–patient communication,
(2) motivating patients to influence their doctors to
engage in SDM, (3) teaching SDM skills in continuing
medical education, residency and medical school and (4)
requiring SDM discussions as a quality standard in
caring for patients between the ages of 50 and 75.
Interventions that the group felt would require the most
effort included (1) providing patients with tools that
allowed them to prepare for their meeting with the
physician, (2) providing doctors with tools to assist in
discussions with men and (3) providing specific ob-
served feedback to physicians on their counseling and
SDM skills.
Patients. Panelists more easily reached consensus about
interventions to improve cancer communication for
patients than for providers (Table 2). The group
recommended development of a trusted website
(information source) that could serve as a one-stop home
for high-quality information and decision support
interventions on cancer screening. Such a site could use
current quality assessment guidelines34 to consider which
decision support interventions to include/credential. Within
the group, there were divisions between the views of
specialists and primary care providers about the
appropriateness of information related to screening and
treatment from a population perspective. Given that the
disagreements are unlikely to be resolved, such a website
would need to be evidence-based and peer-reviewed; it
should avoid being all things to everyone. Participants
acknowledged differences between social groups in
addressing issues of related to cancer and health screening.
Based on the ranking, the most effective strategies to
improve patient PrCS decision-making include: (1) making
reliable and accurate educational tools publicly available
and (2) empowering patients to have direct conversations
with the physicians. Participants also felt men should be
engaged outside of the doctor–patient encounter to learn:
(1) the importance of making medical decisions in the face
of uncertainty; (2) that they can choose various levels of
involvement with their doctor, from no involvement to
complete involvement; (3) information about the medical
condition (prostate cancer) and the decision that needs to be
made (to screen or not).
The participants felt the most effective cancer communi-
cation intervention directed at patients would be to move
some education about PrCS away from the doctor–patient
encounter to learning programs, including group meetings
led by non-physician health educators. Patient small-group
meetings focused on health education have been quite
effective in helping patients manage their chronic ill-
nesses.35 Such meetings could play an important role in
preparing patients to interact with their physicians, answer
common questions and thus reduce time needed for doctor–
patient discussions.
They also suggested a pre-visit phone call to get patients
thinking about these issues as well as framing PrCS
discussions as attempts to keep them healthy, not just to
look for cancer.
Figure 1. Two-part model of elements influencing medical decisions around complex medical decisions
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Table 1. Improving Physician Behaviors Around Prostate Cancer Screening Discussions
Average rank
for effectiveness
in achieving
behavioral
change (1–7,
7=maximum)
Theme Item Barriers to change related to each item Average rank
for effort to
achieve
change (1–7,
7=maximum)
6.9 Financial and
regulation
Change reimbursement to
incentivize doctor–patient
communication
• If you don’t pay you won’t get it done 3.3
• Will cost systemmoney to increase time for clinicians
6.9 Communication
and messaging
Have consumers apply pressure
to physicians to engage in SDM
• Will require process to inform/motivate patients 5.4
• Will need to have advocacy groups take on this agenda
• Notable expenses for such campaign
6.9 Education and
knowledge
Teach shared decision-making skills
(with good and poor examples) in
continuing medical, residency and
medical school education
• Teaching skills is for more difficult than teaching
knowledge and will require models, practice and
feedback
4.8
6.9 Financial and
regulation
Implement SDM and cancer
screening communication as
quality standard (e.g., pay for
performance) and adjust
reimbursement
• May obtain minimal performance, with just
checkboxes EMR measures
3.3
• Regulation is “easy” for EMR capable
systems—developing the standard of care is
difficult
6.7 Financial and
regulation
Do not allow PSA test ordering
until there is documentation of
SDM in the EMR
• Will require that each EMR be set up to disallow
ordering until documentation is provided
5.8
6.4 Communication
and messaging
Provide clinicians with
interactive tools to allow men
to visualize risks and benefits
and aid in their understanding
(e.g., smart phone apps)
• Will need development, funding and regular updating. 6.2
• Will need to be done by CDC or other credible source
6.3 Financial and
regulation
Benchmark PSA testing by
providing data on other
provider’s PSA testing rates
• Could be done within & between group practices 4.6
6.2 Communication
and messaging
Provide clear and simple
messages that providers can use
with their patients
• Such messages need to be in a central repository
or database and be easily accessible.
5.8
5.9 Communication
and messaging
Provide table of effective
preventive strategies based on
the expected benefit to the
patient so that patients and
providers can allocate their time
appropriately
•Needs to be produced by credible source 5.9
• Needs to be disseminated
• Needs to be simple and understandable to both
patients and providers
5.9 Communication
and messaging
Convey in messaging that groups
are “making money” from testing
decisions
• Will be politically difficult 5.6
• Will create inter-professional discord
• Will need to be done by outside advocacy groups
5.5 Education and
knowledge
Provide direct observational
feedback to clinician on their
counseling and shared decision-
making skills
• Easier to do in medical school and residency 6.2
• No real mechanism to do this in practice
• Could more easily be done by health care systems
(such as VA or Kaiser) where such resources and
motivation exists
5.4 Education and
knowledge
Provide guidelines on when to
use SDM and when to use more
directed decision-making
• Such education is difficult to disseminate
and is best done in training programs not in CME
environments
5.8
5.0 Financial and
regulation
Use accreditation lever
(mandatory testing or module
completion for recertification)
• Will require broad buy-in from multiple
constituencies
4.1
4.4 Financial and
regulation
Work with professional
organizations to promote
awareness and skill building
• This would need to involve many professional
and advocacy groups
4.2
4.3 Financial and
regulation
Prevent ordering of PSA test unless
it is linked to patient SDM signed
note (using HIVas a model)
• Requires both system approval and programming
of the EMR
3.5
4.0 Communication
and messaging
Re-label “prostate cancer” to
another name that better captures
the varied nature of abnormal cells
• At best will be a slow evolution and there are
powerful forces who will continue to push for it to
be considered “cancer”
3.3
3.9 Behavior Provide data to providers on
patients (or percentage of patients)
who don’t opt in to PSA testing so
they know that not everyone is
selecting “testing”
• Will require each health care system or laboratory
to compile this data separate
5.9
• If you do this nationally it may not have
as much meaning to any given provider or patient
3.6 Behavior Measure quality of care in the
doctor–patient encounter and
provide bonus when SDM is done
well (may be more related to
physician than patient)
Would have cost implications to physicians and
health care systems
2.0
PSA: prostate-specific antigen, SDM: shared decision-making, EMR: electronic medical record, VA: Veterans Administration, NNT: number needed
to treat, NNH: number needed to hard
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Health Care Systems. Not surprisingly, many of the
communication approaches recommended for health care
systems were complex and costly (Table 3). Participants felt
an essential step would be to change reimbursement
strategies so that time spent on careful PrCS discussions
would be adequately reimbursed. The cost-effectiveness of
this strategy would need to be examined, with a likely
reduction in low-yield testing, biopsies and surgery. The
group also encouraged creative thinking around developing
incentives intended to improve physical PrCS communication.
Almost all participants endorsed the idea to incentivize
documentation of SDM as a regularly monitored quality
control measure but recognized the difficulties that would
surround implementation.
Participants expressed the concern that health care systems
should take responsibility for helping men to understand they
have choices in health care as well as giving them the
knowledge and tools to make informed decisions. They
suggested that celebrities might be more effective at commu-
nicating messages than traditional approaches such as mailings
or posters in doctor’s offices. They strongly encouraged
development of interactive, engaging and customizable
eLearning tools that could be used in the office or provided to
individuals (apps or web-based decision support interventions)
Table 2. Patient Issues Around Prostate Cancer Screening Discussions
Average rank
for effectiveness
in achieving
behavioral
change (1–7,
7=maximum)
Theme Item Barriers to change related to each
item
Average rank
for effort to
achieve change
(1–7,
7=maximum)
5.5 Education and
knowledge
Provide tools to patients that allow them to
prepare and learn about cancer screening,
before they meet with the doctor to
improve use of visit time
• Dissemination will be a problem, best
managed by health care systems or
advocacy groups
6.8
• Will require high level of patient
related literacy
• Will need to address different education
levels and different languages and cultural
groups
• Will need to be kept up to date
• Will require a national curriculum
5.5 Behavior Unbundle cancer screening discussions
from PCP visit and place in “wellness
clinic” or “group prevention clinic”
• Would need to rearrange clinic and
staff, and patient flow/scheduling
3.6
5.2 Behavior Provide pre-visit phone call (or other
communication) perhaps from staff to prime
patient on content and questions to ask
• Would need to have system to deliver
these calls
3.8
4.9 Attitudes and
beliefs
Pay attention to framing effect. Reframe
discussions as health promotions vs.
detection of cancer/disease
• Would need to develop tools and have
system and clinician buy-in
4.3
4.8 Education and
knowledge
Use of high quality decision aides in
doctor–patient interactions
• Would need to develop tools and have
system and clinician buy-in
4.5
4.8 Communication
and messaging
Provide messaging around the benefits of
not testing and the concept that “less may
be more”
• Would need to develop tools and have
system and clinician buy-in
4.5
4.6 Communication
and messaging
Encourage patients to be as involved in
decision-making to the as they wish to be
• Would need to develop method of
delivery/dissemination of value scales
and educational materials
4.6
• Knows there is a decision to be made • Physicians might be put off by patients
who wanted more time and explanation
than they could provide
• Knows there are various levels of
involvement they can choose
• Knows a bit about the decision
• Knows what questions to ask
4.4 Financial and
regulation
Waive co-payment or provide other
incentives for patients that engage in SDM
• Would have cost implications to
physicians and health care systems
3.4
• May have small, but important effect
4.1 Attitudes and
beliefs
Have patients be explicit about how much
they value different outcomes (being free of
cancer, being free of side effects, etc.)
• Would need to develop tools and find
appropriate time and setting to assess
values
4.0
• Preferences are often not predictive of
actions made when confronted with
actual decisions
• Would need to explain screening and
side effects in understandable manner
taking into account educational level,
culture and language
3.3 Education and
knowledge
Provide patients with life expectance
calculators, dashboards and guidelines to
review with their doctors
• Requires additional development 3.4
3.3 Education and
knowledge
Provide value assessment tools for
patients to complete
• Should be incorporated seamlessly
into EHRs and decision-aids
3.0
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and that would interface with the electronic health records. For
instance, clinicians could then review patient responses on
values/preferences for SDM around prostate cancer screening.
Doctors could then direct discussion to specific areas of
confusion or uncertainty. Most importantly, participants felt
these decision support interventions would be most useful to
clinicians by allowing them to focus available time on areas
that deserved the most attention and also allow quality
monitoring of physician–patient communication and deci-
sion-making.
DISCUSSION
Screening for cancer raises complex issues involving risks
and benefits to the patient. The ultimate screening decision
Table 3. Improving Health System Behaviors and Public Education Around Prostate Cancer Screening Discussions
Average rank for
effectiveness in
achieving behavioral
change (1–7,
7=maximum)
Theme Item Barriers to change related to
each item
Average rank
for effort to
achieve
change (1–7,
7=maximum)
5.7 Attitudes and
beliefs
Use EMR to educate men around notion that
they have a choice in health care and they
need to be active participants in decision-
making
• Dissemination and outreach will
be crucial
5.8
• Will take time to change
expectations and roles
• Will take time and resources to
develop tools
5.3 Communication
and messaging
Use celebrities to counter detail the pro-
testing message and provide credible
messages around asking questions
• Celebrities may question motives 4.6
• Costly
5.0 Education and
knowledge
Provide education around myths and
misconceptions about cancer screening
• Will need tool to disseminate and
many men may not have access or
sophistication with web-based
tools
3.3
4.9 Communication
and messaging
Partner with other health care organizations
and support groups
• Will require development of
partnerships and trust
4.3
• Would be best if all primary care
groups would stand together on
this issue
4.9 Behaviors Provide non-physicians health educators to
engage in communication and counseling
• Would need to hire/retrain staff to
accomplish task
3.8
4.8 Education and
knowledge
Provide education so that the public
understand that/procedures have harms and
benefits
• Will need tool to disseminate.
Many men may not have access or
experience with web-based tools
3.4
4.7 Behaviors Work with EMR programmers to provide
reminders and tools to assist in SDM in
office or prior to visit
• Will require health care systems
to engage in providing tools to
patients
4.5
4.4 Financial and
regulation
Learn from mammogram and anticipate
strong opposition from those with much to
lose
• The two scenarios may not be
identical
3.9
4.3 Financial and
regulation
Increase visit time • Would have cost implications to
physicians and health care systems
2.2
4.0 Education and
knowledge
Create national curriculum on health care
screening
• Would be large effort with large
costs and multiple constituencies
2.9
3.8 Behaviors Use interactive tools (apps or web tools) that
link to the electronic medical record to
collect answers from patients to questions
about their values, preferences or areas of
uncertainty. Once in the EMR this
information will then be used by clinicians
to guide their discussions
• Will be hard to get experts to
agree
4.8
• Physicians will not like it if it
extends time
• Patients often can not remember
to bring medication list to
doctor—will need reminders
• Will need to tailor message to
different groups
3.7 Attitudes and
beliefs
Separate the economics of cost saving from
evidence for and against testing
• This may require more advanced
discussion than most men would
care to know
3.4
3.6 Communication
and messaging
Convey that the pro-testing community is
being supported by those who make profit
off the test (3)
• Caution in not wanting to create
negative messaging
3.6
3.5 Communication
and messaging
Provide information on screening tests
that are effective and those that are not
(NNT and NNH), as well as cost-
effectiveness 13 and 15
• Will need tool to disseminate
and many men may not have
access or sophistication with
web-based tools
4.4
2.9 Attitudes and
beliefs
Use word other than screening in that
screening is perceived as a general good 8
• Will be hard to do this on a
national level and it will take
years
3.2
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belongs to the patient informed by best evidence, expert
judgment and personal values, and acquisition of clear
information is of paramount importance. Information aside,
cancer screening discussions are often emotional and
influenced by personal, professional and societal factors.
This expert panel on communication about prostate cancer
screening sought to determine methods to both provide
high-quality information and help individuals make value-
concordant health choices.
Importantly, our panelists included a variety of stake-
holders. Their viewpoints differed, as each group was
familiar with a different piece of the prostate cancer
screening puzzle. For instance, patient advocates often
wanted to protect patients from the harms of testing that
were not honestly or openly discussed and from perceived
biased viewpoints of specialists. The primary care physi-
cians treated many of the complications of surgery or
radiation and did not directly see the benefit of population-
level prostate cancer screening. Specialists saw patients
who had or were worried about advanced cancer; they
strongly believed their procedures saved lives and improved
the quality of men’s lives. When our group came to an
impasse over a specific perspective, we acknowledged
disagreement and moved on to discussion in other areas.
By addressing intervention effectiveness, these recom-
mendations are intended to help providers and others
determine the wisdom of particular strategies in pursuit of
value-concordant PrCS decision-making. Clearly, potential
effectiveness is dependent upon using the right social lever
for the right condition—design, engagement strategy and
implementation must all be thoroughly considered.23
Multi-faceted interventions utilizing social media, health
messages and financial incentives may improve PrCS
decision-making. For example, coupling public health
announcements on tobacco cessation in California with an
increase in cigarette sales tax led to significant decreases in
cigarette consumption.36–38 Policies that regulate salt inges-
tion are predicted to reduce blood pressure, risks of
cardiovascular disease and provide substantial savings.39
Similarly, doubling the price of alcohol is projected to reduce
alcohol-related and sexually transmitted diseases by
6%.40,41 These social policy changes do not address
informed decision-making in clinical care but instead
use other societal levers to improve day-to-day decisions
leading to the adoption of healthy behaviors. The
financial impact of these interventions on the lives of
patients was enough to make individual reconsider the
value of a cigarette or a drink at the time of purchase.
As such, panel participants recommended consideration
of new financial/regulatory incentives to improve physi-
cian-patient communication around prostate cancer
screening to supplement emerging decision-support
technology. For instance, financial incentives may
encourage patients to discuss cancer screening and
preventive behaviors with their physicians-and provide
the opportunity for physicians to more thoughtfully
engage patients around the risks and benefits of specific
interventions.
The panelists strongly encouraged more innovative use of
new social and interactive media tools to improve both
physician and patient decision-making, rather than simply
improving knowledge acquisition.42 Decision support inter-
ventions (including for prostate cancer screening) present
information in an understandable manner, have been shown
to increase knowledge, reduce decisional conflict, clarify
values and lead patients to take a more active role in their
health care.31,32 Decision support interventions have been
shown on meta-analysis to reduce PrCS with PSA.43
However, these patient-focused decision support interven-
tions are infrequently used in clinical practice, often due to
lack of awareness of the tools, the additional time taken to
utilize the tool or the lack of access to the tool at the point
of care.31,32 Well-constructed decision support interventions
(icon arrays, stadium diagrams, roulette wheels) address the
complexity of medical and numerical information, biases and
incorporate patient preferences. Our group emphasized that
having a trusted central site (such as within AHRQ, AAMC
MedPortal or CDC) with vetted programs would help
overcome some of the access issues. System redesign might
be necessary to help with decision-aid implementation, with
additional time/space allocated to have patients (and physi-
cians) review the decision support interventions. Such aids can
provide useful customized output to prepare patients for a
discussion with their health care provider.23,44–51
Participants felt that improved physician communication
skills should be addressed through educational interventions
at three levels-medical school (undergraduate medical
education), residency training (graduate medical education)
and continuing medical education. Residency programs are
increasingly emphasizing patient-oriented outcomes, with
attention being paid to enhanced communication skills.52
Evidence suggests that traditional CME does not effectively
improve physician practice-based behaviors or decisions,53–55
and CME has tended to ignore assisting clinicians to improve
communication skills. Assessment, feedback interventions
and recertification examinations offer opportunities to increase
clinically meaningful outcomes if they can focus more on
clinical behaviors than on factual recall. Panel members also
felt that offering providers financial incentives is a tool to
facilitate improved decision-making.
Health systems also have an important role to play in
improving communications around PrCS, including sys-
tem and clinic flow changes to systematize screening
educational resources, discussions and incentives. Some
health care systems have found great success in using
reminders to stimulate communication around specific topics
(via electronic medical records, emails and social networks).
These systems can be expensive, but early reports indicate
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they seem to reduce overall costs and improve quality (Kaiser
Permanente, personal communication).
In summary, effective communication around prostate
cancer screening is essential to match available evidence with
patient values and desires. This article provides a background
for how such communication might be approached from the
perspective of providers, patients and the health care system.
While all of the suggested interventions require resources to
develop and evaluate, the lessons learned now will enhance
screening communication in the future.
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